Milestone Pharmaceuticals Inc (MIST)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $64.74M
Last updated: Nov 17, 2026 at 11:05 AM ET
Milestone Pharmaceuticals Inc (MIST) Stock Forecast
Analysts expect Milestone Pharmaceuticals (MIST) to earn -$0.84 per share in the fiscal year ending Dec 31, 2026, on revenue of $3.49M. Of 7 analysts, 6 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 7 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 86% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 14.3% |
| Buy | 5 | 71.4% |
| Hold | 1 | 14.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 7
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 461.9%.
- Fiscal year ending Dec 31, 2026
- -$0.84
- EPS consensus, revenue $3.49M
- Fiscal year ending Dec 31, 2027
- -$0.78
- EPS consensus, revenue $19.61M
- Next report
- Mar 18, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.84 | -$0.90 to -$0.77 | 5 | $3.49M | $2.80M to $5.30M | 7 |
| Dec 31, 2027 | -$0.78 | -$0.96 to -$0.59 | 5 | $19.61M | $8.80M to $34.60M | 7 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.23 | -$0.26 to -$0.21 | 9 | $1.85M | $1.08M to $3.15M | 9 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 0 upward and 2 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.83.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.84 | -$0.84 | -$0.84 | -$0.84 | -$0.83 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.78 | -$0.78 | -$0.77 | -$0.77 | -$0.91 | N/A |
Frequently Asked Questions About MIST
What is the MIST stock forecast?
Consensus analyst estimates put Milestone Pharmaceuticals's EPS at -$0.84 for the fiscal year ending Dec 31, 2026, on revenue of $3.49M. The consensus rating from 7 analysts is Buy.
How do analysts rate MIST stock?
Of 7 analysts covering Milestone Pharmaceuticals, 1 rates it Strong Buy, 5 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from MIST next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.84, with estimates from -$0.90 to -$0.77 from 5 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.78, with estimates from -$0.96 to -$0.59 from 5 analysts.
What revenue do analysts expect from Milestone Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $3.49M, with estimates from $2.80M to $5.30M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $19.61M, with estimates from $8.80M to $34.60M.
How many analysts cover MIST?
7 analysts rate Milestone Pharmaceuticals stock, and 5 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
MIST pages: Overview, Earnings, Forecast, Financials, Competitors